Logo-npj
Submitted: 25 Jan 2017
Accepted: 02 Apr 2017
ePublished: 12 Apr 2017
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2017;6(2): 138-141.
doi: 10.15171/npj.2017.21
  Abstract View: 8573
  PDF Download: 4628
  Full Text View: 6

Original

The effect of allopurinol on the progression of chronic kidney disease

Aygul Ozdemir, Ayca Inci*

1 Antalya Training and Research Hospital, Nephrology Department, Antalya, Turkey
*Corresponding Author: *Corresponding author: Ayca Inci, , Email: aycainci2004@hotmail.com

Abstract

Introduction: Hyperuricemia has been associated with the development of hypertension,
cardiovascular, and renal disease.

Objectives: We conducted a prospective study to investigate the benefits of allopurinol
treatment in hyperuricemic patients with chronic kidney disease (CKD) stage 3.

Patients and Methods: Our study includes a total of 132 patients (41 females and 91 males)
with CKD grade 3 who are followed up by the pre-dialysis polyclinic. Around 67 of these
patients administered allopurinol while 65 patients were not administered. The therapy
protocol for the patients was allopurinol 150 mg/d and the duration of the follow-up was 12
months. Clinical records of the patients were screened, to start with 3, 6, 9 and 12 months,
eGFR (estimated glomerular filtration rate) values were calculated.

Results: The patients’ eGFR with allopurinol treatment was increased compared with baseline
values. 12th month increased by 1.02 ± 8.89 mL/min/1.73 m2 from baseline in eGFR, but it was
not statistically significant (P = 0.352). In the control group 12th month showed a decrease in
baseline GFR value of 2.59 ± 7.9 mL/min/1.73 m2 (P = 0.012). The 3, 6, 9, 12th months compared
with baseline in the allopurinol treatment group showed a significant decrease in uric acid
value (P < 0.05).

Conclusion: Decreased renal progression was observed by reduction of serum uric acid levels
at stage 3 hyperuricemic CKD with allopurinol. The annual decline in GFR in hyperuricemic
patients, is more than normouricemic patients.


Implication for health policy/practice/research/medical education:

 
Hyperuricemia has been associated with the development of hypertension, cardiovascular, and renal disease. We conducted a prospective study to investigate the benefits of allopurinol treatment in hyperuricemic patients with chronic kidney disease stage three and showed that with allopurinol administration annual decline in glomerular filtration rate in hyperuricemic patients, is slower than normouricemic patients.


Please cite this paper as:
Ozdemir A, Inci A. The Effect of allopurinol on the progression of chronic kidney disease. J Nephropharmacol. 2017;x(x):x-x. DOI: 10.15171/npj.2017.22.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 8574

Your browser does not support the canvas element.


PDF Download: 4628

Your browser does not support the canvas element.


Full Text View: 6

Your browser does not support the canvas element.